Upland Software, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Upland Software, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $74.77M | Mar 30, 2017 |
| FY2016 | Dec 31, 2015 | $69.91M | Mar 30, 2017 |
| FY2014 | Dec 31, 2014 | $64.57M | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | $41.19M | Mar 31, 2015 |
| FY2014 | Dec 31, 2012 | $22.76M | Mar 31, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $216.88M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $274.79M | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $297.85M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $317.30M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $302.02M | Nov 7, 2024 |
| FY2022 | Dec 31, 2020 | $291.78M | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | $66.07M | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | $55.07M | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | $53.01M | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | $48.49M | Mar 2, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $27.85M | Mar 9, 2018 |
| FY2017 | Sep 30, 2017 | $26.07M | Mar 9, 2018 |
| FY2017 | Jun 30, 2017 | $23.28M | Mar 9, 2018 |
| FY2017 | Mar 31, 2017 | $20.75M | Mar 9, 2018 |
| FY2017 | Dec 31, 2016 | $19.37M | Mar 9, 2018 |
| FY2017 | Sep 30, 2016 | $19.24M | Mar 9, 2018 |
| FY2017 | Jun 30, 2016 | $18.57M | Mar 9, 2018 |
| FY2017 | Mar 31, 2016 | $17.58M | Mar 9, 2018 |
| FY2016 | Dec 31, 2015 | $17.60M | Mar 30, 2017 |
| FY2016 | Sep 30, 2015 | $17.11M | Mar 30, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $162.12M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $193.70M | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $201.49M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $213.56M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $202.56M | Nov 7, 2024 |
| FY2022 | Dec 31, 2020 | $193.33M | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | $44.99M | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | $38.39M | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | $36.43M | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | $33.71M | Mar 2, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($38.90M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($112.73M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | ($179.87M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | ($68.41M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | ($58.21M) | Nov 7, 2024 |
| FY2022 | Dec 31, 2020 | ($51.22M) | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | ($19.87M) | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | ($12.31M) | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | ($5.37M) | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | ($7.83M) | Mar 2, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.43M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($102.30M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | ($163.92M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | ($40.23M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | ($34.68M) | Nov 7, 2024 |
| FY2022 | Dec 31, 2020 | ($23.81M) | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | ($12.51M) | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | ($3.70M) | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | ($5.53M) | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | ($2.57M) | Mar 2, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.51M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $47.37M | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $49.38M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $46.19M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $42.69M | Nov 7, 2024 |
| FY2022 | Dec 31, 2020 | $39.00M | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | $8.55M | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | $7.43M | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | $7.01M | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | $6.40M | Mar 2, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.80M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $24.24M | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $49.94M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $29.98M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $41.74M | Nov 7, 2024 |
| FY2022 | Dec 31, 2020 | $35.62M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $12.08M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $7.35M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $7.72M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $3.88M | Mar 15, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.35M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $882.0K | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $1.22M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $866.0K | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $1.12M | Nov 7, 2024 |
| FY2022 | Dec 31, 2020 | $1.11M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $1.04M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $935.0K | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $396.0K | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $670.0K | Mar 15, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $413.18M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $529.52M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $870.02M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $1.11B | Nov 7, 2024 |
| FY2022 | Dec 31, 2021 | $1.03B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $1.01B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $896.83M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $483.20M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $281.26M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $150.59M | Mar 9, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $332.47M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $424.60M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $626.09M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $692.30M | Nov 7, 2024 |
| FY2022 | Dec 31, 2021 | $712.72M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $704.61M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $683.97M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $395.89M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $189.84M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $91.58M | Mar 9, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($48.37M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($18.31M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $126.29M | Mar 3, 2026 |
| FY2025 | Dec 31, 2022 | $308.87M | Mar 3, 2026 |
| FY2024 | Dec 31, 2021 | $316.29M | Mar 12, 2025 |
| FY2023 | Dec 31, 2020 | $306.62M | Nov 7, 2024 |
| FY2022 | Dec 31, 2019 | $212.86M | Mar 1, 2023 |
| FY2019 | Dec 31, 2018 | $87.31M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $91.42M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $59.01M | Mar 9, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $259.63M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $260.98M | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $353.78M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $477.04M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $457.47M | Nov 7, 2024 |
| FY2022 | Dec 31, 2020 | $383.60M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $346.13M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $225.32M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $154.61M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $69.10M | Mar 15, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($640.51M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($601.60M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($488.87M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($309.00M) | Nov 7, 2024 |
| FY2022 | Dec 31, 2021 | ($240.59M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($182.37M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($131.05M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($85.68M) | Mar 2, 2020 |
| FY2018 | Jan 1, 2018 | ($74.84M) | Mar 15, 2019 |
| FY2018 | Dec 31, 2017 | ($81.13M) | Mar 15, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.40M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $56.43M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $236.56M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $248.65M | Nov 7, 2024 |
| FY2022 | Dec 31, 2021 | $189.16M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $250.03M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $175.02M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $16.74M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $22.33M | Mar 15, 2019 |
| FY2018 | Dec 31, 2016 | $28.76M | Mar 15, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $232.41M | Mar 3, 2026 |
| FY2024 | Dec 31, 2024 | $290.19M | Mar 12, 2025 |
| FY2023 | Dec 31, 2023 | $476.67M | Nov 7, 2024 |
| FY2022 | Dec 31, 2022 | $514.98M | Mar 1, 2023 |
| FY2021 | Dec 31, 2021 | $518.33M | Feb 24, 2022 |
| FY2020 | Dec 31, 2020 | $521.60M | Feb 25, 2021 |
| FY2019 | Dec 31, 2019 | $525.07M | Mar 2, 2020 |
| FY2016 | Dec 31, 2016 | $47.93M | Mar 30, 2017 |
| FY2016 | Dec 31, 2015 | $23.87M | Mar 30, 2017 |
| FY2015 | Dec 31, 2014 | $23.29M | Mar 30, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | (5) | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Nov 7, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Feb 24, 2022 |
| FY2018 | Dec 31, 2018 | 0 | Mar 15, 2019 |
| FY2018 | Sep 30, 2018 | 0 | Mar 15, 2019 |
| FY2018 | Jun 30, 2018 | 0 | Mar 15, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | (5) | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Nov 7, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 2, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 29.12M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | 28.17M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | 29.91M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | 32.22M | Nov 7, 2024 |
| FY2022 | Dec 31, 2021 | 31.10M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 29.99M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 25.25M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 21.49M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | 20.77M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | 17.79M | Mar 9, 2018 |